NASDAQ:AIXC Qualigen Therapeutics (AIXC) Stock Price, News & Analysis $1.29 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$1.17 -0.12 (-9.30%) As of 05/22/2026 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock About Qualigen Therapeutics Stock (NASDAQ:AIXC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Qualigen Therapeutics alerts:Sign Up Key Stats Today's Range$1.27▼$1.3650-Day Range$1.06▼$1.5752-Week Range$0.92▼$8.81Volume48,513 shsAverage Volume42,762 shsMarket Capitalization$26.11 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California. Read More Qualigen Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks9th Percentile Overall ScoreAIXC MarketRank™: Qualigen Therapeutics scored higher than 9% of companies evaluated by MarketBeat, and ranked 69th out of 79 stocks in the manufacturing sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingQualigen Therapeutics has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageQualigen Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Qualigen Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Qualigen Therapeutics is -0.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Qualigen Therapeutics is -0.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioQualigen Therapeutics has a P/B Ratio of 1.59. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.44% of the float of Qualigen Therapeutics has been sold short.Short Interest Ratio / Days to CoverQualigen Therapeutics has a short interest ratio ("days to cover") of 1.46, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Qualigen Therapeutics has recently decreased by 24.25%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldQualigen Therapeutics does not currently pay a dividend.Dividend GrowthQualigen Therapeutics does not have a long track record of dividend growth. News and Social MediaN/ANews SentimentN/A Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Qualigen Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders1.17% of the stock of Qualigen Therapeutics is held by insiders.Percentage Held by Institutions3.18% of the stock of Qualigen Therapeutics is held by institutions.Read more about Qualigen Therapeutics' insider trading history. Receive AIXC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Qualigen Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AIXC Stock News HeadlinesHead to Head Contrast: Qualigen Therapeutics (NASDAQ:AIXC) versus Evotec (OTCMKTS:EVTCY)May 16, 2026 | americanbankingnews.comAIxCrypto Announces First Quarter 2026 Earnings Release Date and Conference Call DetailsMay 8, 2026 | prnewswire.com$30 stock to buy before Starlink goes public (WATCH NOW!)A little-known stock pick with money-doubling potential over the next year is revealed for free in the first three minutes of a new video. This company is a critical piece of Elon Musk's fast-growing Starlink technology. It could climb 100 percent or more over the next year as Elon brings Starlink public in what may be the biggest IPO in history. No credit card is required to get the ticker.May 25 at 1:00 AM | Paradigm Press (Ad)AIxCrypto Co-CEO Jerry Wang Shares Weekly Investor Update: Agentir Progress, Chutes AI Collaboration Framework, and Bitcoin 2026 EngagementMay 5, 2026 | prnewswire.comAIxCrypto Announces Strategic Collaboration Framework with Chutes AI to Support AI Agent Infrastructure ScalingApril 30, 2026 | prnewswire.comAIxCrypto's Designated Investor and Faraday Future Complete Amendment to $12 Million Investment Agreement,Exploring RWA-Related Applications and Integration of Real-World Assets with Blockchain InfrastructureApril 17, 2026 | prnewswire.comAIxCrypto Co-CEO Jerry Wang Shares Weekly Investor Update: RWA Exploration, Ecosystem Development, and External EngagementApril 14, 2026 | prnewswire.comAIxCrypto Co-CEO Jerry Wang Shares Weekly Investor Update: AI Agent Development and Internal Testing ProgressApril 6, 2026 | prnewswire.comSee More Headlines AIXC Stock Analysis - Frequently Asked Questions How have AIXC shares performed this year? Qualigen Therapeutics' stock was trading at $2.17 at the beginning of 2026. Since then, AIXC shares have decreased by 40.6% and is now trading at $1.29. How were Qualigen Therapeutics' earnings last quarter? Qualigen Therapeutics, Inc. (NASDAQ:AIXC) issued its quarterly earnings results on Tuesday, May, 12th. The company reported ($0.79) earnings per share for the quarter. How do I buy shares of Qualigen Therapeutics? Shares of AIXC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings5/12/2026Today5/25/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (4m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 AIXC's financial health is in the Red zone, according to TradeSmith. AIXC has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorManufacturing Industry Pharmaceutical Preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AIXC CIK1460702 WebN/A Phone(760) 918-9165Fax760-918-9127Employees50Year FoundedN/AProfitability EPS (Trailing Twelve Months)($6.47) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$16.97 million Net MarginsN/A Pretax MarginN/A Return on Equity-771.52% Return on Assets-79.52% Debt Debt-to-Equity RatioN/A Current Ratio11.57 Quick Ratio11.57 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.81 per share Price / Book1.59Miscellaneous Outstanding Shares20,240,000Free Float19,998,000Market Cap$26.11 million OptionableN/A Beta0.52 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free Report This page (NASDAQ:AIXC) was last updated on 5/25/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredRead now. Do not delete. You’ve been warned.Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” P...Porter & Company | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Qualigen Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Qualigen Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
